# Thomas Berg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-berg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,565 |
| Field | Hepatitis C virus research |
| h-index | 110 |
| i10-index | 564 |
| Last Known Institution | Leipzig University of Applied Sciences |
| OpenAlex ID | https://openalex.org/A5082309779 |
| ORCID iD | https://orcid.org/0000-0003-0003-6241 |
| Works | 1,583 |

## Researcher papers

- [EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection](https://scholariq.org/papers/easl-2017-clinical-practice-guidelines-on-the-management-of-hepatitis-b-virus/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis](https://scholariq.org/papers/a-genome-wide-association-study-confirms-pnpla3-and-identifies-tm6sf2-and-mboat7/)
- [The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology](https://scholariq.org/papers/the-predict-study-uncovers-three-clinical-courses-of-acutely-decompensated/)
- [Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis](https://scholariq.org/papers/chymotrypsin-c-ctrc-variants-that-diminish-activity-or-secretion-are-associated/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis](https://scholariq.org/papers/effect-of-sarcopenia-on-survival-in-patients-with-cirrhosis-a-meta-analysis/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients](https://scholariq.org/papers/role-of-the-galad-and-balad-2-serologic-models-in-diagnosis-of-hepatocellular/)
- [PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis](https://scholariq.org/papers/predict-identifies-precipitating-events-associated-with-the-clinical-course-of/)
- [GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis](https://scholariq.org/papers/galad-score-detects-early-hepatocellular-carcinoma-in-an-international-cohort-of/)
- [A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis](https://scholariq.org/papers/a-degradation-sensitive-anionic-trypsinogen-prss2-variant-protects-against/)

## Researcher topics

- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [Leipzig University of Applied Sciences](https://scholariq.org/institutions/leipzig-university-of-applied-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.